Emma Reeve
Independent Board Director
Emma Reeve is a global finance executive and board director who has focussed on life sciences for over 25 years, with experience in pharmaceutical, medical device and bio-pharma service companies. Most recently she was Chief Financial Officer of Constellation Pharmaceuticals, a development-stage oncology company, where she led the IPO in 2018, raised over $600 million in public and private financial offerings and was a key member of the team that sold the company to MorphoSys AG in 2021. Now Emma’s focus is her board portfolio. She is Chair of the board of Editas Medicine (EDIT) and serves on the boards of PTC Therapeutics (PTCT), Aadi Bioscience (AADI), Ribon Therapeutics and Cardurion Pharma. She is Audit Committee Chair for each company and also has experience serving on Compensation Committees and Nominating and Governance Committees. Emma also serves as a member of the Board of Trustees of Tufts Medical Center. Emma’s strengths lie in leading businesses to value-creation milestones and building high-performance teams. She has robust experience in business transformation and change management, as well as raising capital and M&A. Immediately prior to Constellation Pharmaceuticals, as Chief Financial Officer at NASDAQ-listed bio-pharmaceutical services company Parexel International, Emma had responsibility for all aspects of finance, investor relations, procurement and facilities, leading a team of over 950 people. She was the finance lead in a sell-side process that culminated in the transfer of the company to private equity ownership in a $4.9 billion leveraged buy-out. Emma has held senior finance roles in major pharmaceutical companies: Novartis, Merck and Bristol Myers Squibb. Through different positions across Europe and the USA at the country, regional and corporate levels she has gained a deep understanding of the global pharmaceutical industry. Emma was Chief Financial Officer of two private biotech companies prior to Constellation Pharmaceuticals. At Aton Pharma she was a lead member of the team that sold the company to Merck in a ground-breaking contingent-value-rights (CVR) deal. As CFO of Inotek Pharmaceuticals she was a key member of the team that partnered the lead oncology asset with Genentech and was successful in raising equity financing for the company in a tough capital market.